BeyondSpring

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the PRC and U.S. geographical segments. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in New York, NY.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. It operates through the Plinabulin Pipeline and TPD Platform segments. The Plinabulin Pipeline segment focuses on the development of cancer therapies. The TPD Platform segment engages in the development of therapeutic agents and discover chemical entities. The company was founded by Lan Huang and Lin Qing Jia in 2010 and is headquartered in Florham Park, NJ.

NEW YORK, Oct.  24, 2019  (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global clinical stage biopharmaceutical company focused on the development and commercialization of innovative immuno-oncology cancer therapies, today announced the launch of an underwritten public offering of its ordinary shares. The offering is being led by Decheng Capital. The Company also expects to grant the underwriters an option to purchase up to an additional 15% of the ordinary shares being offered. The Company intends to use the net proceeds of this offering to support continued clinical and pre-clinical development and for general corporate purposes.

BeyondSpring Announces - Proposed Public Offering of Ordinary Shares

Novel Findings Published in Peer-Reviewed Cell Journals Chem and Cell Reports Novel Findings Published in Peer-Reviewed Cell Journals Chem and Cell Reports

Cell Journals Publishes BeyondSpring’s New Data on Mechanism of Plinabulin to Mature Dendritic Cells, Leading to T-Cell Activation

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q2 2019 Results - Earnings Call Transcript

- To Submit New Drug Applications (“NDAs”) in China for Both Non-Small Cell Lung Cancer (“NSCLC”) and Chemotherapy-Induced Neutropenia (“CIN”) in Q1 2020 -

BeyondSpring Provides Operational Update and Second-Quarter 2019 Financial Results

NEW YORK, Sept.  10, 2019  (GLOBE NEWSWIRE) --  BeyondSpring Inc.  (NASDAQ: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that the Company’s novel design for Study 103 was selected for poster presentation at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer in Barcelona, Spain. The poster, titled “DUBLIN-3, a Phase (Ph) III Trial Comparing the Plinabulin (P) / Docetaxel (D) Combination with D Alone in Stage IIIB / IV NSCLC,” was presented on September 9 from 10:15 a.m.-6:15 p.m. local time.

BeyondSpring’s Novel Study 103 Phase 3 Design in NSCLC To Be Presented at 2019 IASLC World Conference on Lung Cancer

NEW YORK, Sept.  06, 2019  (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a global biopharmaceutical company focused on the development of innovative cancer therapies, announced today that management will provide a corporate overview at the H.C. Wainwright 21st Annual Global Investment Conference in New York, NY on Tuesday, September 10, 2019, at 10:00 a.m. Eastern Time.

BeyondSpring to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Data to be Presented at IASLC 2019 World Conference on Lung Cancer Data to be Presented at IASLC 2019 World Conference on Lung Cancer

BeyondSpring’s Plinabulin Demonstrates Superior Quality of Life Over Pegfilgrastim in a Head-to-Head Comparison Trial for the Prevention of Neutropenia

BeyondSpring Inc. (BYSI) CEO Lan Huang on Q4 2018 Results - Earnings Call Transcript

Neulasta has been the mainstay of treatment for chemotherapy-induced neutropenia.

BeyondSpring: Improving Neulasta's Efficacy And Safety In Chemotherapy-Induced Neutropenia

News for BeyondSpring Stock (BYSI)